Tacrolimus 0.1% in Severe Pediatric Vernal Keratoconjunctivi
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Tacrolimus 0.1% eye drops in a large population of pediatric patients affected by a severe form of vernal keratoconjunctivitis (VKC) was found to be Safe & Efficacious. The aim of this study was to evaluate the safety and efficacy of tacrolimus 0.1% eye drops who responded poorly to cyclosporine eye drops.

This is a retrospective study based on standardized clinical charts and data collecting of consecutive patients with severe VKC who failed to react to topical cyclosporine eye drops but were treated with tacrolimus 0.1 percent eye drops with an 18-month follow-up. Hyperemia, tarsal papillae, gigantic papillae, and limbal papillae were all graded for analysis. The results of blood tests for kidney and liver function, as well as the level of tacrolimus, were examined. At the beginning of the study, as well as at 3, 6, 12, and 18 months, visits were arranged. Patients were given tacrolimus 0.1 percent eye drops twice a day in both eyes.

--431 patients were included. 325 patients were affected by a seasonal form, whereas the remaining 106 by a perennial form.
--Statistical analysis on each single score showed a positive relevance from baseline to all other visits.
--No local or systemic complications were recorded.

Finally, Tacrolimus has been offered as a therapy option for severe VKC. The safety and efficacy of tacrolimus  0.1 % eye drops in a large pediatric population of patients with a severe form of VKC who did not respond well to cyclosporine eye drops were confirmed in this study.

Source: https://journals.lww.com/corneajrnl/Abstract/9000/Long_Term_Safety_and_Efficacy_of_Tacrolimus_0_1_.95751.aspx